Breast Cancer

Board recommends continuation of Entremed's MKC-1 Phase II breast cancer study

Published in Clinical Oncology Week, February 19th, 2007

EntreMed, Inc. (ENMD) announced a favorable review of MKC-1 safety data by an independent Data Safety Monitoring Board (DSMB). The review was undertaken to assess the safety of MKC-1 in a Phase II multi-center clinical trial in patients with advanced or metastatic breast cancer who have failed conventional therapies.

The DSMB concluded that the apparent risk, based on the current safety data review for MKC-1, was appropriate for the population under study. The DSMB also felt that the study did not require any modification, and that the Phase II study in patients with metastatic breast cancer should continue as currently designed. The study is being conducted at multiple...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2007-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry